Journal of Applied Hematology

REVIEW ARTICLE
Year
: 2019  |  Volume : 10  |  Issue : 4  |  Page : 111--119

Oral anticoagulants: Optimizing venous thromboembolism management


Fahad A S. Aleidan 
 Department of Basic Medical Science, College of Medicine, King Saud bin Abdulaziz University for Health Sciences; Department of Clinical Pharmacology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Correspondence Address:
Dr. Fahad A S. Aleidan
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh
Saudi Arabia

A decade ago, oral anticoagulants were limited to Vitamin K antagonists, i.e., warfarin. Since 2010, the US Food and Drug Administration has approved several non-Vitamin K oral anticoagulants: dabigatran is a direct thrombin inhibitor, while apixaban, edoxaban, and rivaroxaban are direct factor Xa inhibitors. Oral anticoagulants are used for the management of several venous thromboembolism (VTE) events, including the prevention of stroke in nonvalvular atrial fibrillation; acute coronary syndromes; treatment of VTE; and VTE prophylaxis after total hip or knee replacement. In this review article, we address the main indications, dosages, bleeding and reversal agents, pharmacokinetic and pharmacodynamic properties, and methods of switching between oral anticoagulants.


How to cite this article:
S. Aleidan FA. Oral anticoagulants: Optimizing venous thromboembolism management.J Appl Hematol 2019;10:111-119


How to cite this URL:
S. Aleidan FA. Oral anticoagulants: Optimizing venous thromboembolism management. J Appl Hematol [serial online] 2019 [cited 2020 Apr 4 ];10:111-119
Available from: http://www.jahjournal.org/article.asp?issn=1658-5127;year=2019;volume=10;issue=4;spage=111;epage=119;aulast=S.;type=0